In the last trading session, 1,367,617 shares of the Epizyme, Inc. (NASDAQ:EPZM) were traded, and its beta was 1.34. Most recently the company’s share price was $8.65, and it changed around -$0.77 or -0.08% from the last close, which brings the market valuation of the company to $880.44 Million. EPZM currently trades at a discount to its 52-week high of $22, offering almost -154.34% off that amount. The share price’s 52-week low was $7.44, which indicates that the current value has risen by an impressive 13.99% since then. We note from Epizyme, Inc.’s average daily trading volume that its 10-day average is 1.65 Million shares, with the 3-month average coming to 1.1 Million.
Epizyme, Inc. stock received a consensus recommendation rating of Overweight, based on a mean score of 2.1. If we narrow it down even further, the data shows that none out of 9 analysts rate the stock as a Sell; another but none rate it as Overweight. Among the rest, 3 recommended EPZM as a Hold, whereas 6 deemed it a Buy, and no one rated it as Underweight. Epizyme, Inc. is expected to report earnings per share of -$0.58 for the current quarter.
Epizyme, Inc. (NASDAQ:EPZM): Trading Information
Although EPZM has showed a red trend with a performance of -8.17% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of $9.44- on Monday, Apr 05 increased the stock’s daily price by 8.32%. The company’s shares are currently down -0.2% year-to-date, but still up 0.1611 over the last five days. On the other hand, Epizyme, Inc. (NASDAQ:EPZM) is -0.09% down in the 30-day period. We can see from the shorts that 12.09 Million shares have been sold at a short interest cover period of 10.99 day (s).
The consensus price target as assigned by Wall Street analysts is $18.89, which translates to bears needing to increase their stock price by 118.38% from its current value. Analyst projections state that EPZM is forecast to be at a low of $10 and a high of $36. In order for the stock price to hit the forecast high, the stock would need to surge +316.18% from its current level, while the stock would need to crash 15.61% from its current level to reach the projected low.
Epizyme, Inc. (EPZM) projections and forecasts
Consensus estimates provided by 7 financial analysts predict the company will bring in an average of $6.63 Million in revenue for the current quarter. 7 analysts expect Epizyme, Inc. to make $9.24 Million in revenue for the quarter ending June 01, 2021. The company’s sales for the same quarter a year ago was $1.35 Million. Analysts predict that the company’s current quarter sales will jump, forecast at 389.7%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 7.1%. Epizyme, Inc. earnings are expected to decrease by -19.1% in 2021, but the outlook is positive 38% per year for the next five years.
Epizyme, Inc. (NASDAQ:EPZM)’s Biggest Investors
Upon looking at major shareholders, it appears that insiders hold 4.17% of Epizyme, Inc. shares, and 99.11% of them are in the hands of institutional investors. The stock currently has a share float of 103.42%. Epizyme, Inc. stock is held by 207 institutions, with Primecap Management Company being the largest institutional investor. By Dec 30, 2020, it held 14.94% of the shares, which is about 15.21 Million shares worth $165.16 Million.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Redmile Group, LLC, with 9.28% or 9.45 Million shares worth $102.63 Million as of Dec 30, 2020, holds the second largest percentage of outstanding shares.
Primecap Odyssey Aggressive Growth Fund and Primecap Odyssey Growth Fund were the top two Mutual Funds as of Jan 30, 2021. The former held 9757107 shares worth $106.84 Million, making up 9.59% of all outstanding shares. On the other hand, Primecap Odyssey Growth Fund held roughly 4.69 Million shares worth around $51.32 Million, which represents about 4.6% of the total shares outstanding.